Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Tempus is a healthtech company that leverages artificial intelligence (AI), big data, and genomic sequencing to revolutionize precision medicine. By analyzing vast amounts of medical and molecular data, Tempus empowers doctors and researchers to make data-driven decisions that improve patient outcomes. But what exactly does Tempus do, and why is it a game-changer in the healthcare industry? Let’s explore.
Founded in 2015 by entrepreneur Eric Lefkofsky, Tempus is headquartered in Chicago, Illinois. The company operates at the intersection of healthcare and technology, using AI and machine learning to transform how diseases are diagnosed and treated. Tempus primarily focuses on oncology, neurology, cardiology, and infectious diseases, with a strong emphasis on cancer research and personalized medicine.
Tempus conducts advanced genomic sequencing to analyze a patient’s DNA, RNA, and proteins. This helps doctors identify specific genetic mutations that may influence disease development and treatment response.
✅ Enables personalized treatment plans for cancer and other diseases.
✅ Identifies biomarkers that help in drug selection and clinical trials.
Tempus has built one of the largest clinical and molecular data libraries in the world. Using AI, it provides physicians with real-time insights that guide treatment decisions.
✅ Helps doctors compare patient cases with similar profiles.
✅ Recommends optimized treatment options based on data-driven insights.
Tempus is particularly known for its contributions to oncology, helping oncologists design customized cancer treatments using AI and genomic data.
✅ Assists in detecting tumor mutations and potential drug targets.
✅ Supports immunotherapy and targeted therapy approaches.
Tempus connects patients with clinical trials based on their genetic and clinical data, increasing access to cutting-edge treatments.
✅ Increases patient eligibility for new therapies.
✅ Helps pharmaceutical companies accelerate drug discovery.
By analyzing massive datasets, Tempus helps pharmaceutical companies and researchers develop new drugs faster and more efficiently.
✅ Predicts how patients will respond to certain drugs.
✅ Identifies new therapeutic targets using AI.
Tempus offers tools for remote patient monitoring, collecting real-world data to track disease progression and treatment effectiveness.
✅ Helps doctors monitor patients remotely using AI-driven insights.
✅ Enhances predictive analytics to foresee health risks.
The CEO of Tempus AI is Eric Lefkofsky, a well-known entrepreneur and investor. He co-founded Tempus in 2015 with the vision of using artificial intelligence and big data to revolutionize precision medicine. Lefkofsky is also the co-founder of several successful companies, including Groupon, Echo Global Logistics, and Uptake Technologies. With a strong background in technology and business, he has played a key role in transforming Tempus into one of the leading AI-driven healthcare companies, helping doctors and researchers leverage data for better patient care.
Tempus AI is headquartered in Chicago, Illinois, USA. The company operates from its main offices in the city’s tech and business hub, where it focuses on developing cutting-edge AI solutions for healthcare. In addition to its headquarters, Tempus collaborates with hospitals, research institutions, and pharmaceutical companies across the United States and internationally. With its strong presence in the medical technology space, Tempus continues to expand its influence, shaping the future of precision medicine and AI-driven healthcare solutions.
Tempus is redefining how healthcare data is used to diagnose and treat diseases. By combining AI, genomic sequencing, and real-world evidence, Tempus helps physicians, researchers, and pharmaceutical companies deliver more effective, data-driven treatments. As the demand for precision medicine continues to grow, Tempus is playing a crucial role in shaping the future of healthcare.